Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies. The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies. The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Study Type
OBSERVATIONAL
Enrollment
500
Medical University Innsbruck
Innsbruck, Austria
NOT_YET_RECRUITINGAntwerp University Hospital
Antwerp, Belgium
NOT_YET_RECRUITINGChildren's Hospital Zagreb
Zagreb, Croatia
NOT_YET_RECRUITINGMotol University Hospital
Prague, Czechia
NOT_YET_RECRUITINGCharacterizing disease progression in pediatric and adult patients with type I interferonopathies
Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.
Time frame: 2025-2045
Identifing and characterising genotype-specific immunological factors
Description of specific immunological factors according to genotype
Time frame: 2025-2045
Research of biomarkers for diagnosis, prognosis and monitoring of disease activity
Biomarkers identified for diagnosis, prognosis and monitoring of disease activity
Time frame: 2025-2045
Monitoring of treatment response according to phenotype and genotype
Treatment response by phenotype and genotype
Time frame: 2025-2045
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU d'Angers
Angers, France
RECRUITINGHôpital de Mercy - CHR Metz Thionville
Ars-Laquenexy, France
NOT_YET_RECRUITINGCHU de Besançon
Besançon, France
RECRUITINGCHU de Bordeaux
Bordeaux, France
NOT_YET_RECRUITINGCHU Morvan
Brest, France
RECRUITINGHôpital Femme Mère Enfant - HCL
Bron, France
RECRUITING...and 22 more locations